







KidneyDiagnostic Performance of a Saliva Urea
Nitrogen Dipstick to Detect Kidney Disease
in Malawi
Rhys Evans1,2,3,9, Viviane Calice-Silva4,5,9, Jochen G. Raimann6, Ulla Hemmila1,2,
Alison Craik2, Mwayi Mtekateka2, Fergus Hamilton2, Zuze Kawale2, Hamish Dobbie3,
Gavin Dreyer7, Nathan Levin8, Peter Kotanko6 and Roberto Pecoits-Filho4; in collaboration
with the International Society of Nephrology (ISN) 0by25 Initiative
1Department of Medicine, College of Medicine, Blantyre, Malawi; 2Nephrology Department, Queen Elizabeth Central Hospital,
Blantyre, Malawi; 3Department of Renal Medicine and Transplantation, Barts Health, Royal London Hospital, London, UK;
4School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil; 5Division of Nephrology, Pró-rim Foundation,
Joinville, Brazil; 6Research Division, Renal Research Institute, New York, USA; 7Nephrology Department, Royal Free Hospital,
London, UK; and 8Icahn School of Medicine at Mount Sinai, New York, USAIntroduction: Kidney disease (KD), including acute kidney injury, is common, severe and leads to signif-
icant mortality in the developing world. However, simple tools to facilitate diagnosis and guide treatment
are lacking. We studied the diagnostic performance of saliva urea nitrogen (SUN) measured by dipstick to
diagnose KD in a low-resource setting.
Methods: Medical admissions to a tertiary hospital in Malawi had serum creatinine tested at presentation;
SUN was measured using a dipstick. Patients with serum creatinine above normal range underwent serial
measurements of SUN and blood urea nitrogen for up to 7 days. Hospital outcome was recorded in all
patients.
Results: A total of 742 patients were included (age 41  17$3 years, 56.1% male); 146 (19.7%) had KD,
including 114 (15.4%) with acute kidney injury. SUN >14 mg/dl had a sensitivity of 0.72 and a speciﬁcity of
0.87 to diagnose KD; speciﬁcity increased to 0.97 when SUN levels were combined with self-reported urine
output. The diagnostic performance of SUN was comparable with the one of blood urea nitrogen (SUN
area under curve, 0.82; 95% conﬁdence interval, 0.78–0.87; blood urea nitrogen area under curve, 0.82;
95% conﬁdence interval, 0.59–1.0). SUN >14 mg/dl on admission was an independent predictor of all-
cause mortality (hazard ratio ¼ 2.43 [95% conﬁdence interval, 1.63–3.62]).
Discussion: SUN measured by dipstick can be used to identify patients with KD in a low-resource setting.
SUN is an independent predictor of mortality in this population.
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International Reports (2017) 2, 219–227Many deaths resulting from AKI in low-resource
settings (LRS) may be preventable.5 However, a num-
ber of major challenges exist when managing AKI in
these areas: (i) a disparity in health care resources
available in urban compared with rural areas; (ii) poor
awareness among patients and health care workers of
AKI and the need for its early detection and treatment;
(iii) a scarcity of trained personnel and resources for
renal replacement therapy; and (iv) a lack of reliable
and cost-effective tools to diagnose AKI.5,6
The lack of medical and laboratory infrastructure
in LRS makes the development of an inexpensive,
noninvasive, and reliable bedside diagnostic tool to
identify patients with kidney disease (KD), including
AKI, essential.5 Saliva urea nitrogen (SUN) was ﬁrst219
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since evaluated the diagnostic capability of SUN to
detect renal impairment.8–11 SUN parallels blood urea
nitrogen (BUN) and urea reaches saliva by diffusive
transport from the salivary glands. Alongside bicar-
bonate, it is responsible for the buffering capacity of
saliva.12 SUN concentration can vary according to
stimulation of the salivary glands and the amount
of saliva produced. SUN can be measured by
laboratory techniques but also by a simple dipstick
method.13
The SUN dipstick has been suggested as a potential
screening tool for acute and chronic KD.14,15 Indeed, in
our previous studies in developed settings, SUN strips
demonstrated good diagnostic performance to detect
kidney dysfunction, especially at the higher levels of
BUN.14 In the present study, we aimed to explore the
diagnostic performance of this tool in a LRS, where
access to laboratory measurements of renal function is
often limited, and where the SUN test may be of
greatest value.
METHODS
Study Design, Setting, and Participants
We conducted a prospective observational study at
Queen Elizabeth Central Hospital in Blantyre, Malawi,
one of the poorest countries in the world. Queen Eliz-
abeth Central Hospital acts as both a district hospital
and a tertiary hospital for the southern region of
Malawi, although the majority of patients admitted are
from Blantyre district itself, with a population of
approximately 1 million.
All patients aged 14 years or older admitted to the
general medical wards between 27 April 2015 and 17
July 2015 were eligible. Patients unable to give
informed consent, patients transferred to the medical
ward from another ward or hospital, and patients
who were unable to provide a sufﬁcient volume of
saliva (including those with signiﬁcantly reduced
level of consciousness) were excluded from the
study.
Patients enrolled were screened for KD with serum
creatinine (sCR) measurement. Concomitantly, we
measured SUN levels using a dipstick (Integrated
Biomedical Technology, Elkhart, IN). Those with sCR
above the local laboratory reference range (>90 mmol/l
in women; >104 mmol/l in men) were managed by the
nephrology team and followed with serial SUN, BUN,
and sCR measurements for a period of up to 7 days or
until hospital discharge if sooner. Demographic and
clinical data, including signs and self-reported symp-
toms (increased thirst and reduced urine output) of
altered volume status, were also recorded. Hospital
outcome was recorded in all patients.220Data Collection
Saliva and blood samples were collected simultaneously
on admission (day 0) for the measurement of SUN and
sCR, and then at 24 hours (day 1) and every 48 hours
thereafter (days 3, 5, and 7) for the measurement of
SUN, BUN, and sCR.
SUN Measurement
SUN was assessed using a dipstick (Integrated
Biomedical Technology). Subjects were asked to
refrain from drinking and eating for at least 15 mi-
nutes prior to saliva collection. Unstimulated saliva
was collected in a plastic cup and approximately
50 ml of saliva was used to moisten the test pad of a
colorimetric SUN dipstick. The dipstick test pad
contains a urease enzyme in a bound form that
cleaves SUN when moistened with saliva; this
leads to the formation of ammonia and hydroxyl
ions resulting in a change in pH which, by a pH
indicator substance, consequently changes color of
the test pad. After 1 minute, the color of the test pad
is compared with 6 reference pads indicating
increasing SUN concentrations: 5–14 mg/dl (pad 1),
15–24 mg/dl (pad 2), 25–34 mg/dl (pad 3),
35–54 mg/dl (pad 4), 55–74 mg/dl (pad 5), and$75 mg/dl
(pad 6) (Figure S1).15
sCR and Urea Measurement
sCR was measured by the Jaffe method16 and BUN by
the urease method17 (either by Flexor Junior Clinical
Chemistry Analyzer [Vital Scientiﬁc, Dieren, The
Netherlands] or by Mindray Chemistry Analyzer
BS-120 [Shenzhen Mindray Bio-Medical Electronics
Company, Shenzhen, China]) in a local laboratory.
Deﬁnitions
AKI, acute kidney disease/disorder (AKD) without AKI,
and chronic kidney disease were diagnosed and staged
by Kidney Disease Improving Global Outcomes
criteria.1,18 KD is used to refer to AKI, AKD without
AKI, and stable chronic kidney disease. AKD
incorporates both conﬁrmed AKI and AKD without
AKI (Figure S2).
Outcome Measures
The primary outcome measure was the diagnostic
performance of the SUN dipstick to detect KD, alone
and in combination with self-reported changes in
urine output and thirst. Secondary outcome measures
were the agreement of SUN with BUN at presentation
and during management of KD, and the ability
of SUN to predict in-hospital mortality in this
population.
Statistical Analyses
For the statistical analyses, urea results were converted
to BUN (mg/dl) and SUN was transformed to aKidney International Reports (2017) 2, 219–227
Figure 1. Cohort description. AKD, acute kidney disease/disorder;
AKI, acute kidney injury; BUN, blood urea nitrogen; CKD, chronic
kidney disease; NKD, no kidney disease; SUN, saliva urea nitrogen.
R Evans et al.: SUN Dipstick to Detect Kidney Disease in Malawi CLINICAL RESEARCHcontinuous variable by choosing the midpoint for each
range. Descriptive statistics were presented as mean
 SD and as median and interquartile range, depending
on data distribution.
The agreement between SUN and BUN was tested by
one-way analysis of variance with a post hoc Bonferroni
correction formultiple testing. Differences betweenBUN
and SUN (midpoint concentration of the respective test
pad range) were displayed as error bars (with 95%
conﬁdence intervals [CI]) at different days and repre-
sented as a modiﬁed Bland-Altman plot using BUN as the
reference method.19 Agreement between SUN and BUN
over the entire period was also tested using linear mixed
effects models with random intercepts for each subject
and random slopes for each 2-day period.
Diagnostic performance of SUN and BUN to detect KD
was analyzed using sensitivity and speciﬁcity, and by
the area under the receiver operating characteristics
curve at each of the observation days. Optimal
diagnostic thresholds were determined based on the
maximumYouden’s index (Youden’s index¼ sensitivity
þ speciﬁcity 1). In addition, sensitivity and speciﬁcity
were used to evaluate the diagnostic performance of SUNTable 1. Demographics, SUN, and serum creatinine levels on admission
N (count) Age (yr)
All patients 742 40.8  17.3
No kidney disease 596 40.1  17.2
AKI stage 1 26 45.9  16.2
AKI stage 2 21 36.5  13.9
AKI stage 3 67 44.4  18
AKD with no AKI 26 47  17
CKD 6 47.7  23.4
AKD, acute kidney disease/disorder; AKI, acute kidney injury; CKD, chronic kidney disease; SU
Kidney International Reports (2017) 2, 219–227to detect KD combined with the 2 self-reported clinical
parameters, namely, increased thirst and reduced urine
output.20
Cox proportional hazard models were constructed to
evaluate the predictors of death in this population.
Age, gender, the presence of diabetes, and SUN levels
were assessed. Kaplan-Meier curves were used to assess
the mortality risk in patients stratiﬁed by the absence
or presence of SUN levels >14 mg/dl (i.e., SUN > test
pad 1). All surviving patients were censored at day 15.
A 2-sided P value less than 0.05 was considered
statistically signiﬁcant. Analyses were done using R
3.2.1 (codename “World-Famous Astronaut”; R Foun-
dation for Statistical Computing, Vienna, Austria).21
RESULTS
Cohort Description
Of 892 medical patients admitted to the hospital during
the study period, 742 had both sCR and SUN mea-
surements and were thus included in the analysis
(Figure 1). The mean age was 41  17 years; 56% were
male. A total of 146 (19.7%) patients had KD: 114
(15.4%) AKI, 26 (3.5%) AKD without AKI, and 6
(0.8%) stable chronic kidney disease. AKI was stage 3
in 67 (58.8%) patients (Table 1).
A total of 130 patients had SUN measured on day 1.
The characteristics of these patients are shown in
Table 2. There were signiﬁcantly more patients with
hypovolemia as determined by the study team, self-
reported reduced urine output, and increased thirst
(60.5%, 29.6%, and 100%, respectively) in the group
with AKI stage 3 compared with the other groups
(Table S1). The most common causes of renal disease
were related to sepsis and hypoperfusion: gastroen-
teritis (n ¼ 24, 18.5%), heart failure (n ¼ 21, 16.15%),
pulmonary and disseminated tuberculosis (n ¼ 13,
10%), and malaria (n ¼ 9, 6.9%).
SUN and BUN Measurements
When comparing results of both parameters, there was
a similar trend over time (Figure S3), with SUN
consistently underestimating BUN in the follow-up
period (Figure 2). However, the agreement betweenin the study population
Male gender (%) SUN (mg/dl) Creatinine (mmol/l)
56.06 16.8  18.6 156  335.8
55.37 11.1  4.8 62.6  20.5
38.46 28.2  24.5 140.7  1.7
61.9 34  26.6 239  111.9
67.16 53  32.6 811.6  704.2
53.85 25.3  27.6 342.3  525.9
66.67 37.5  28.4 886.5  867.3
N, saliva urea nitrogen.
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Table 2. Demographics and biochemical ﬁndings (SUN, BUN, and serum creatinine) in patients who had SUN measured on day 1
N (count) Age (yr) Male gender (%) SUN (mg/dl) BUN (mg/dl) Creatinine (mmol/l)
No kidney disease 21 42  20.3 71.43 15.7  5.9 32.4  35.6 100.1  23.6
AKI stage 1 23 45.5  16.7 39.13 23.7  22.6 37.7  21.4 130.5  44.4
AKI stage 2 17 36.5  10.8 58.82 22.7  8.5 35.9  19.1 193.9  91.7
AKI stage 3 44 41.1  16.3 72.73 46.4  31.7 92.4  44.8 760.1  761.6
AKD with no AKI 20 45.1  16.2 55 24.8  24 45.3  34.5 309  442.7
CKD 5 50.2  25.3 60 25.5  5.5 75.7  58.1 820.2  970.6
All 130 42.3  6.8 61.54 30.2  25.8 57.7  44.2 403.3  583.4
AKD, acute kidney disease/disorder; AKI, acute kidney injury; BUN, blood urea nitrogen; CKD, chronic kidney disease; SUN, saliva urea nitrogen.
Figure 2. Scatterplot demonstrating the relationship between saliva urea nitrogen and blood urea nitrogen on days 1, 3, 5, and 7.
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treatment (Figure 3). Plotting the differences (BUN –
SUN midpoint) as a function of BUN and as a modiﬁed
Bland-Altman plot showed consistent nonsigniﬁcant
biases and proportional errors (Figure 4).
When BUN is stratiﬁed by SUN categories, analysis of
variance with Bonferroni correction did not show sig-
niﬁcant differences between the lower test pad numbers
(e.g., test pads 1 and 2, or 2 and 3); however, signiﬁcant
differences were seen when lower test pads were
comparedwith test pads that reﬂect higher levels of SUN
(e.g., test pad 1 and pads 3–6, or test pads 2–4 and 6)
(Table S2). These differences suggest improved perfor-
mance of SUN to diagnose KD at more elevated BUN
levels but lower accuracy of SUN at lower levels of BUN.
Longitudinal data analysis of BUN as a predictor of
SUN using a linear mixed effects model showed BUN to
signiﬁcantly associate with SUN (0.26 mg/dl SUN
increase per 1 mg/dl BUN increase; P < 0$001).
Diagnostic Performance of SUN and BUN
The area under the receiver operator characteristics
curve for SUN to detect KD decreased from 0.82 (95%
CI, 0.78–0.85) on observation day 0 (screening day) to
0.69 (95% CI, 0.50–0.78) on observation day 1Figure 3. Point estimates and 95% conﬁdence intervals of the dif-
ference between blood urea nitrogen (BUN) and saliva urea nitro-
gen (SUN) (quantiﬁed as the midpoint of the categories of the
dipstick) on days 1, 3, and 5.
Kidney International Reports (2017) 2, 219–227(Figure 5). Sensitivity and speciﬁcity were highest at
day 0 (0.71 and 0.87, respectively). The optimal diag-
nostic threshold for SUN to diagnose KD was test pad 2
(based on the maximum Youden’s index according to
the sensitivity and speciﬁcity of SUN at day 0). For
BUN, the area under the receiver operator characteris-
tics curve was 0.82 (95% CI, 0.59–1.0) on day 1
(Figure 6). The sensitivity and speciﬁcity of patient-
reported oliguria alone to detect KD in this cohort
was 0.3 and 0.79, respectively. Self-reported increased
thirst analyzed combined with SUN >14 mg/dl (SUN
>test pad 1) did not show signiﬁcant improvement in
the sensitivity and speciﬁcity to detect KD. When
analyzing self-reported decreased urine output com-
bined with SUN >14 mg/dl (SUN >test pad 1) to di-
agnose KD, signiﬁcant differences in the sensitivity
(0.22) and speciﬁcity (0.97) were demonstrated.
Although sensitivity is low, the speciﬁcity increased
by 0.1 up to 0.97 when self-reported information on
urine output was added.
Outcome Analyses
Hospital outcome was determined in 702 patients. Of
these patients, 104 (14$8%) died, with 17 (2.4%)
doing so after the censoring at day 15. Age, gender,
the presence of diabetes, and SUN results were eval-
uated as predictors of time to in-hospital death;
elevated SUN >14 mg/dl (SUN > test pad 1) was the
only factor that was a signiﬁcant independent pre-
dictor of all-cause mortality (hazard ratio ¼ 2.23 [95%
CI, 1.50–3.32]) (Figure 7).
DISCUSSION
Simple and inexpensive bedside tools aiding diagnosis
and guiding treatment of KD are lacking. The main
ﬁnding of this study was that SUN measured by a
dipstick demonstrated good diagnostic performance
and longitudinal agreement with BUN in patients with
predominantly AKD in an LRS in sub-Sahara Africa.
The results conﬁrm earlier reports on the agreement
between SUN and BUN.14,15 In addition, they corrob-
orate the notion that SUN dipsticks can be used for
monitoring the evolution of renal function.22 Of note,
BUN and SUN agreed well throughout all observation
days, with SUN consistently reﬂecting BUN levels over
time. Our data also corroborate previous ﬁndings of
SUN levels being lower than BUN.14,15,22 Furthermore
we conﬁrmed good agreement between BUN and SUN
at higher levels of BUN, but a lower level of accuracy of
SUN to detect more subtle changes in renal function.
The diagnostic performance of SUN to detect KD
decreased over the course of the study period, which
may be explained by treatment initiation on admission
resulting in decreased BUN and consequently SUN223
Figure 4. Bland-Altman plot indicating the difference between blood urea nitrogen (BUN) and saliva urea nitrogen (SUN) as a function of the
BUN on days 1, 3, 5, and 7. Dotted lines represent the mean difference  SD at each observation day. The data indicate a consistent systematic
and proportional bias consistent throughout the observation period.
CLINICAL RESEARCH R Evans et al.: SUN Dipstick to Detect Kidney Disease in Malawilevels. As a consequence, sensitivity and speciﬁcity
during the follow-up period was affected. In addition,
loss to follow-up needs to be considered that affects not
only sample size and subsequently the CI, but also the
distribution of disease and diagnostic markers in
the respective population analyzed at each day. For the
concept of the current manuscript we deemed the
results on day 0 as most important.
In this study, a level of SUN >14 mg/dl (SUN > test
pad 1) was identiﬁed as the optimal threshold to
diagnose KD at day 0 (screening day), with good224sensitivity and speciﬁcity (0.71 and 0.87, respectively).
When assessing the diagnostic performance of SUN
levels combined with the information regarding urine
output, we found a higher speciﬁcity to diagnose KD
(0.97) at the expense of lower sensitivity (0.22). These
ﬁndings demonstrate that SUN strips have a better
screening performance (sensitivity) to detect KD when
applied alone but a better diagnostic performance to
exclude those without KD (speciﬁcity) when used
combined with patient-reported urine output. This is
of signiﬁcant clinical relevance in an LRS. Patients atKidney International Reports (2017) 2, 219–227
Figure 5. Receiver operating characteristic curves of saliva urea nitrogen to detect kidney disease (acute kidney injury [AKI], acute kidney
disease/disorder without AKI, and chronic kidney disease) on days 0 and 1. AUC, area under curve.
R Evans et al.: SUN Dipstick to Detect Kidney Disease in Malawi CLINICAL RESEARCHhigh risk for AKI (e.g., suffering from malaria or other
infectious illness) are routinely evaluated at health
centers and district hospitals by health care workers
with only basic medical training and without access to
laboratories.23 Signiﬁcant numbers of patients at risk ofFigure 6. Receiver operating characteristic curves of blood urea
nitrogen to detect kidney disease (acute kidney injury [AKI], acute
kidney disease/disorder without AKI, and chronic kidney disease) on
day 1. AUC, area under curve.
Kidney International Reports (2017) 2, 219–227KD are seen each day. We feel the SUN dipstick may be
a useful clinical tool for these health care workers to
use alongside clinical evaluation of the patient to try
and identify those patients at highest risk of KD and
poor outcome. According to the data in this study, a
patient, for example, without a change in self-reported
urine volume and a SUN less than 15 mg/dl (i.e., testFigure 7. Kaplan-Meier analysis demonstrating survival probability
for all patients stratiﬁed by the presence or absence of saliva urea
nitrogen (SUN) >14 mg/dl (i.e., SUN > test pad 1).
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believe this is powerful information to have.
Moreover, given the SUN strip’s diagnostic perfor-
mance demonstrated in this study, and its consistent
agreement with BUN on all observation days, our data
suggest that SUN may be a suitable tool not only to
screen for AKI but also to monitor treatment progres-
sion in LRS, and should be considered for use at remote
health care facilities in patients who are being treated
locally for kidney injury. A positive result for SUN
should immediately trigger speciﬁc diagnostic and
therapeutic interventions such as volume assessment
and ﬂuid replacement as appropriate (oral or i.v.),
avoidance of nephrotoxins, and management of the
underlying disease (e.g., antimicrobials or antimalarial
drugs). A SUN strip suggestive of severe renal injury
(e.g., test pads 3–6), or progressive SUN levels over
time despite treatment, especially in rural areas with
limited health care resources, should trigger referral to
the next level of health care with better infrastructure
and possibly renal replacement therapy.
Elevated SUNwas demonstrated to be an independent
predictor of time to death in this population. This makes
SUN an important additional tool in informing clinicians
about the severity of a patient’s disease process and their
prognosis. In LRS this may trigger more intensive moni-
toring, expedite management, and prompt earlier referral
to the next tier of the health care system with the aim of
increasing the probability of survival for these patients.
There are some limitations of the SUN strips to
highlight. Limitations for the accuracy of the test and
heterogeneity of the results may be related to differ-
ences of salivary ﬂow rate and composition in terms of
circadian rhythms of salivary glands, variable degrees
of patient hydration, and the potential interference of
oral bacterial ﬂora with urea degradation in the cav-
ity.12,24,25 Furthermore, collection of saliva in a patient
with reduced conscious level, while possible, may be
more challenging and was not attempted in this study.
The dipstick quantiﬁes salivary urea, but does
not provide information on other electrolyte levels
(e.g., potassium), which can be done using other more
sophisticated point-of-care devices.
However, there are also major strengths to this tech-
nique. The SUN strip is a relatively cheap (approxi-
matelyUS$1/test strip), noninvasive, bedside tool of easy
application, which allows quick evaluation of renal
function. It does not require power or refrigerated
storage and may therefore be applicable in even the
remotest of settings. In low-middle income countries
wheremanypeople, due to infrastructural,ﬁnancial, and
political issues, often do not receive appropriate diag-
nosis and treatment,2,26 SUN strips could be of great
utility to increase the identiﬁcation of KD, to improve226the diagnostic capability of health care facilities, to raise
awareness about the need of earlier management, and,
above all, to improve patient outcome from AKI.
CONCLUSION
This study is the ﬁrst effort to apply a bedside diag-
nostic tool to detect and follow-up patients affected by
KD in an LRS, in this case in Malawi in sub-Sahara
Africa. Here, as in previous studies in developed set-
tings, SUN demonstrated good diagnostic performance
to screen, diagnose, and follow patients with acute and
chronic kidney injury. Moreover, SUN was shown to
be an independent predictor of all-cause mortality in
this population. Semiquantitative SUN measurements
by a simple dipstick method in parallel with a clinical
evaluation may assist in the diagnosis of AKI, especially
under circumstances of limited health care resource.
Studies will now address the capability of SUN strips to
detect KD in different populations and in even more
rural settings, and assess the impact on patient outcome
of this diagnostic tool.
DISCLOSURE
VC-S was a fellow of the ISN and received scholarship
from the Brazilian Government (CAPES) during part of
the time when the study was conducted. NL and PK hold
stock in Fresenius Medical Care. During this study, RP-F
received a scholarship from the Brazilian Council for
Research Support (CNPq). None of the other authors have
declared competing interests.ACKNOWLEDGMENTS
We acknowledge the generous provision of SUN dipsticks
free of charge by Integrated Biomedical Technology. The
results presented in this paper have not been published
previously. This study was funded by The International
Society of Nephrology (ISN) (Research and Prevention
Program), and The Royal Society of Tropical Medicine and
Hygiene. The role of these organizations was provision of
funding only. The study was approved by the Malawi
College of Medicine Research and Ethics Committee
(P.11/14/1660), and all patients provided written informed
consent at enrollment.
RDRE, VC-S, JGR, HD, GD, NWL, PK, and RP-F designed
the study. RDRE, UH, AC, MM, FH, and ZK collected the
data and managed the study patients. JGR performed
statistical analyses. RDRE and VC-S wrote the manuscript.
All authors revised the manuscript and have approved
the ﬁnal version.SUPPLEMENTARY MATERIAL
Figure S1. Saliva urea nitrogen (SUN) dipstick reference
pads (1–6) of increasing urea nitrogen range.Kidney International Reports (2017) 2, 219–227
R Evans et al.: SUN Dipstick to Detect Kidney Disease in Malawi CLINICAL RESEARCHFigure S2. Deﬁnitions of AKI, AKD without AKI, CKD, and
NKD.
Figure S3. Line plots representing (a) BUN and (b) SUN at
all observation days.
Table S1. Demographic and clinical-related parameters on
day 1 in patients with kidney dysfunction.
Table S2. BUN levels of all patients on all observation days
stratiﬁed as per SUN.
Supplementary material is linked to the online version of
the paper at www.kireports.org.REFERENCES
1. KDIGO AWG. KDIGO 2012 clinical practice guideline for the
evaluation and management of acute kidney injury. Kidney
Int Suppl. 2012;2:19–36.
2. Lewington AJ, Cerda J, Mehta RL. Raising awareness of acute
kidney injury: a global perspective of a silent killer. Kidney Int.
2013;84:457–467.
3. Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an
increasing global concern. Lancet. 2013;382:170–179.
4. Cerda J, Bagga A, Kher V, Chakravarthi RM. The contrasting
characteristics of acute kidney injury in developed and
developing countries. Nat Clin Pract Nephrol. 2008;4:138–153.
5. Mehta RL, Cerda J, Burdmann EA, et al. International Society
of Nephrology’s 0by25 initiative for acute kidney injury (zero
preventable deaths by 2025): a human rights case for
nephrology. Lancet. 2015;385:2616–2643.
6. Lunyera J, Kilonzo K, Lewington A, Yeates K, Finkelstein FO.
Acute kidney injury in low-resource settings: barriers to
diagnosis, awareness, and treatment and strategies to over-
come these barriers. Am J Kidney Dis. 2016;67:834–840.
7. Wright S. Case of ascites in which, during spontaneous pty-
alism that occurred after tapping, urea was detected in saliva.
Lancet. 1841;1:753–758.
8. Akai T, Naka K, Yoshikawa C, et al. Salivary urea nitrogen as
an index to renal function: a test-strip method. Clin Chem.
1983;29:1825–1827.
9. Barnett GD, Bramkamp RG. Inﬂuence of the rate of secretion
on the urea concentration of saliva. Proc Soc Exp Biol Med.
1929;27:118–120.
10. ForlandM, Shannon IL, Katz FH. Parotid-ﬂuid urea nitrogen for
themonitoringofhemodialysis.NEngl JMed. 1964;271:37–38.
11. Hench PS, Aldrich M. The concentration of urea in saliva.
JAMA. 1922;79:1409–1412.Kidney International Reports (2017) 2, 219–22712. Humphrey SP, Williamson RT. A review of saliva: normal
composition, ﬂow, and function. J Prosthet Dent. 2001;85:
162–169.
13. Amerongen AV. Saliva: properties and functions. In:
Wong DT, ed. Salivary Diagnostics. 2nd ed. New Delhi, India:
Wiley-Blackwell; 2008:27–36.
14. Calice-Silva V, Vieira MA, Raimann JG, et al. Saliva urea ni-
trogen dipstick—a novel bedside diagnostic tool for acute
kidney injury. Clin Nephrol. 2014;82:358–366.
15. Raimann JG, Kirisits W, Gebetsroither E, et al. Saliva urea
dipstick test: application in chronic kidney disease. Clin
Nephrol. 2011;76:23–28.
16. Slot C. Plasma creatinine determination. A new and speciﬁc
Jaffe reaction method. Scand J Clin Lab Invest. 1965;17:
381–387.
17. Kay WW, Sheehan HL. Accuracy in the determination of
blood-urea by the urease aeration-titration method. Biochem
J. 1934;28:1784–1794.
18. KDIGO CWG. KDIGO 2012 clinical practice guideline for the
evaluation and management of chronic kidney disease.
Kidney Int Suppl. 2013;2:19–62.
19. Bland JM, Altman DG. Measuring agreement in method
comparison studies. Stat Methods Med Res. 1999;8:
135–160.
20. Weinstein S, Obuchowski NA, Lieber ML. Clinical evaluation
of diagnostic tests. AJR Am J Roentgenol. 2005;184:14–19.
21. Team RDC. R: a language and environment for statistical
computing. Vienna: R Foundation for Statistical Computing;
2010.
22. Raimann JG, Calice-Silva V, Thijssen S, et al. Saliva urea
nitrogen continuously reﬂects blood urea nitrogen after
acute kidney injury diagnosis and management: longitu-
dinal observational data from a collaborative, interna-
tional, prospective, multicenter study. Blood Purif. 2016;42:
64–72.
23. OlowuWA, Niang A, Osafo C, et al. Outcomes of acute kidney
injury in children and adults in sub-Saharan Africa: a sys-
tematic review. Lancet Glob Health. 2016;4:e242–e250.
24. Burne RA, Chen YY. Bacterial ureases in infectious diseases.
Microbes Infect. 2000;2:533–542.
25. Dawes C. Circadian rhythms in human salivary ﬂow rate and
composition. J Physiol. 1972;220:529–545.
26. Anand S, Cruz DN, Finkelstein FO. Understanding acute
kidney injury in low resource settings: a step forward. BMC
Nephrol. 2015;16:5.227
